Impact Biomedical (IBO) Revenue (2022 - 2026)

Impact Biomedical's (IBO) quarterly Revenue came in at $7000.0 in Q1 2026, down 61.11% on a QoQ basis from $18000.0 in Q3 2025.

Impact Biomedical (IBO) Revenue (2022 - 2026) Analysis & Trends

Impact Biomedical (IBO) has 3 years of Revenue data on file, last reported at $7000.0 in Q1 2026.

Quarterly Revenue changed N/A year-over-year to $7000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32000.0 (changed N/A YoY) and the FY2022 annual result came in at $50000.0, changed N/A from the prior year.
Revenue fell to $7000.0 in Q1 2026, from $18000.0 in the prior quarter.
In the past five years, Revenue ranged from a high of $50000.0 in Q2 2022 to a low of $7000.0 in Q2 2025.
A 3-year average of $20500.0 and a median of $12500.0 in 2025 frame the typical range for Revenue.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Vertex Pharmaceuticals	139.66 Bn	131.80 Bn	2.84 Bn	3.33 Bn
2	Regeneron Pharmaceuticals	86.52 Bn	78.53 Bn	3.93 Bn	4.29 Bn
3	Argenx Se	65.33 Bn	60.14 Bn	1.37 Bn	1.52 Bn
4	Moderna	59.76 Bn	54.62 Bn	52.00 Mn	145.00 Mn
5	BeOne Medicines	42.15 Bn	37.05 Bn	1.53 Bn	1.71 Bn
6	Alnylam Pharmaceuticals	31.84 Bn	28.53 Bn	992.69 Mn	1.29 Bn
7	BioNTech SE	28.23 Bn	9.84 Bn	668.28 Mn	1.06 Bn
8	Insmed	27.52 Bn	26.36 Bn	358.27 Mn	425.49 Mn
9	Royalty Pharma	27.29 Bn	26.46 Bn	-	674.14 Mn
10	Impact Biomedical	47.30 Mn	47.29 Mn	2,000.00	3,000.00

Download Data